Ampio regains compliance with NYSE listing standards

Ampio Pharmaceuticals "announced that it has received notification from The NYSE American LLC stating that the Company has regained compliance with the NYSE American’s continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide."